登入 加入會員 求助
 
Changchun Changsheng Life Sciences Ltd.
 
 
Recommended Results 
 
Clinical Inactivated Influenza Vaccine 

  產品分類 : 化學->化學用品->aspalthic products

     
Clinical Inactivated Influenza Vaccine
       

  產品規格
 
Model No:    0.5ml/vial
  Country  CN
  Minimum Order  5000
  Payment Term  L/C,T/T

 

  產品描述
   
  <span>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<b>&nbsp;Influenza Vaccine&nbsp;</b>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Advantage<br />
(1) Apply centrifugal purification and column chromatography purification technology to purifying virus and obtained the patent certificate of making use of Sepharose4FF column chromatography technology for vaccine manufacture. The product quality index is excellent and the purity is high;&nbsp;<br />
(2) Obtained National Ten Famous-brand Products Honor Certificate in pharmaceutical industry;<br />
(3) High-level GMT of conversion rate of serum antibody with safety and reliable effect for prevention;<br />
(4) Various Specifications:<br />
1) Vial type for adult: 0.5ml/vial for people above 3 years old;<br />
Vial type for children:0.25ml/vial for children from 6 to 35 months old;<br />
2) Syringe type for adult: 0.5ml/syringe for people above 3 years old;<br />
Syringe type for children:0.25ml/syringe for children from 6 to 35 months old;<br />
(5) Exclusively apply two dosage forms of pre-filled syringe from American BD Company and vial pack for security and convenience;<br />
(6) Rated as National New and Key Product by the Ministry of Science and Technology, Ministry of Foreign Trade and Economic Cooperation, State General Administration of Supervision, Inspection and Quarantine, State Environmental Protection Administration of China; rated as Excellent Technology Product by China Association for Science and Technology; award the Honor of Science and Technology Progress by Changchun City Administration of Science and Technology;<br />
(7) Successfully registered in over 20 countries and export to dozens of countries for consecutive years.
</p>
<div>
<br />
</div>
&nbsp;
<p>
<br />
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Eligibles<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Function and use<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Description<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. )
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Subsidiary materials: All the components of subsidiary materials approved shall be listed.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span>[</span>Specifications<span>]</span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
0. 25 ml or 0.5 ml per container. &nbsp;0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.
</p>
<img src="http://i.bosscdn.com/product/4b/7c/6b/3e1521af692db14cd8709065d6.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Influenza Vaccine-vial" alt="Influenza Vaccine-vial" /><br />
</span>
<p>
<br />
</p>
<p class="MsoNormal">
<span><br />
</span>
</p>
<p class="MsoNormal">
<br />
</p>ccls-vaccine.com

  其他類似產品
 
Prevent Hepatitis A Virus Vaccine

Prevent Hepatitis A Virus Vaccine
Preventing Chickenpox Immunization Vaccine

Preventing Chickenpox Immunization Vaccine
Clinical Varicella Immunization Vaccine

Clinical Varicella Immunization Vaccine
Clinical hepatitis A vaccine

Clinical hepatitis A vaccine
 
   


[ Back Products Catalog ]

Commerce 會員:
請登入您的 帳號 跟 密碼, 系統將自動為您填入您的相關基本資料!
 
帳號:
密碼:
記住我的帳號
 
 
填寫下列表格並寄送詢問函.所有的詢問信函將會自動寄發給你想聯絡的公司
主旨
內容 ﹙ 請勿輸入公司名稱、Email、電話、傳真、網址 ﹚
   

 


公司簡介:

*公司名稱
*E-mail
*國家
*聯絡人
網址
*電話
- -
傳真
- -
*郵遞區號
*城市
*街道地址
*企業形態
批發商   出口商 進口商 製造商
大盤商 零售商  代理商 Retrofitter 使用者
其他, 請詳細說明:
*安全密碼
請輸入所顯示的安全密碼


網站導覽 l 隱私權政策 l 服務團隊 l 合作提案 l 聯絡我們 l 幫幫我 l 廣告刊登 l  B2B商業夥伴
    .